Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B-cell non-Hodgkin lymphoma

Nam H. Dang; Luis Fayad; Peter McLaughlin; Jorge E. Romaguara; Fredrick Hagemeister; Andre Goy; Sattva Neelapu; Felipe Samaniego; Pamela L. Walker; Michael Wang; Maria A. Rodriguez; Ann T. Tong; Barbara Pro

doi:10.1111/j.1365-2141.2007.06684.x

Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B-cell non-Hodgkin lymphoma

Nam H. Dang, Luis Fayad, Peter McLaughlin, Jorge E. Romaguara, Fredrick Hagemeister, Andre Goy, Sattva Neelapu, Felipe Samaniego, Pamela L. Walker, Michael Wang, Maria A. Rodriguez, Ann T. Tong, Barbara Pro

Lymphoma-Myeloma

Research output: Contribution to journal › Article › peer-review

32 Scopus citations

Abstract

Denileukin diftitox plus rituximab was evaluated in relapsed/refractory B-cell non-Hodgkin lymphoma patients. Of the 38 evaluable patients, 30 (80%) were rituximab-refractory. The overall response rate (ORR) was 32%, with six complete responses (CR) and six partial responses (PR). The median time to progression for responders was 8 months (range: 2-36+); two patients with rituximab-refractory follicular lymphoma were in CR at 25 and 36+ months. The ORR was 55% (4 CRs, 2 PRs) in 11/14 patients with rituximab-refractory follicular lymphoma, and 100% in the three patients with rituximab-sensitive tumour. Most toxicities were low grade and transient, and myelotoxicity was uncommon.

Original language	English (US)
Pages (from-to)	502-505
Number of pages	4
Journal	British Journal of Haematology
Volume	138
Issue number	4
DOIs	https://doi.org/10.1111/j.1365-2141.2007.06684.x
State	Published - Aug 2007

Keywords

Denileukin difitox
Follicular lymphoma
Non-Hodgkin lymphoma
Rituximab

ASJC Scopus subject areas

Hematology

MD Anderson CCSG core facilities

Clinical Trials Office

Access to Document

10.1111/j.1365-2141.2007.06684.x

Cite this

Dang, N. H., Fayad, L., McLaughlin, P., Romaguara, J. E., Hagemeister, F., Goy, A., Neelapu, S., Samaniego, F., Walker, P. L., Wang, M., Rodriguez, M. A., Tong, A. T., & Pro, B. (2007). Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B-cell non-Hodgkin lymphoma. British Journal of Haematology, 138(4), 502-505. https://doi.org/10.1111/j.1365-2141.2007.06684.x

Dang, NH, Fayad, L, McLaughlin, P, Romaguara, JE, Hagemeister, F, Goy, A, Neelapu, S , Samaniego, F, Walker, PL, Wang, M, Rodriguez, MA, Tong, AT & Pro, B 2007, 'Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B-cell non-Hodgkin lymphoma', British Journal of Haematology, vol. 138, no. 4, pp. 502-505. https://doi.org/10.1111/j.1365-2141.2007.06684.x

@article{78069820163d4d18994e30172bc5ed9e,

title = "Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B-cell non-Hodgkin lymphoma",

abstract = "Denileukin diftitox plus rituximab was evaluated in relapsed/refractory B-cell non-Hodgkin lymphoma patients. Of the 38 evaluable patients, 30 (80%) were rituximab-refractory. The overall response rate (ORR) was 32%, with six complete responses (CR) and six partial responses (PR). The median time to progression for responders was 8 months (range: 2-36+); two patients with rituximab-refractory follicular lymphoma were in CR at 25 and 36+ months. The ORR was 55% (4 CRs, 2 PRs) in 11/14 patients with rituximab-refractory follicular lymphoma, and 100% in the three patients with rituximab-sensitive tumour. Most toxicities were low grade and transient, and myelotoxicity was uncommon.",

keywords = "Denileukin difitox, Follicular lymphoma, Non-Hodgkin lymphoma, Rituximab",

author = "Dang, {Nam H.} and Luis Fayad and Peter McLaughlin and Romaguara, {Jorge E.} and Fredrick Hagemeister and Andre Goy and Sattva Neelapu and Felipe Samaniego and Walker, {Pamela L.} and Michael Wang and Rodriguez, {Maria A.} and Tong, {Ann T.} and Barbara Pro",

year = "2007",

month = aug,

doi = "10.1111/j.1365-2141.2007.06684.x",

language = "English (US)",

volume = "138",

pages = "502--505",

journal = "British Journal of Haematology",

issn = "0007-1048",

publisher = "Wiley-Blackwell",

number = "4",

}

TY - JOUR

T1 - Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B-cell non-Hodgkin lymphoma

AU - Dang, Nam H.

AU - Fayad, Luis

AU - McLaughlin, Peter

AU - Romaguara, Jorge E.

AU - Hagemeister, Fredrick

AU - Goy, Andre

AU - Neelapu, Sattva

AU - Samaniego, Felipe

AU - Walker, Pamela L.

AU - Wang, Michael

AU - Rodriguez, Maria A.

AU - Tong, Ann T.

AU - Pro, Barbara

PY - 2007/8

Y1 - 2007/8

N2 - Denileukin diftitox plus rituximab was evaluated in relapsed/refractory B-cell non-Hodgkin lymphoma patients. Of the 38 evaluable patients, 30 (80%) were rituximab-refractory. The overall response rate (ORR) was 32%, with six complete responses (CR) and six partial responses (PR). The median time to progression for responders was 8 months (range: 2-36+); two patients with rituximab-refractory follicular lymphoma were in CR at 25 and 36+ months. The ORR was 55% (4 CRs, 2 PRs) in 11/14 patients with rituximab-refractory follicular lymphoma, and 100% in the three patients with rituximab-sensitive tumour. Most toxicities were low grade and transient, and myelotoxicity was uncommon.

AB - Denileukin diftitox plus rituximab was evaluated in relapsed/refractory B-cell non-Hodgkin lymphoma patients. Of the 38 evaluable patients, 30 (80%) were rituximab-refractory. The overall response rate (ORR) was 32%, with six complete responses (CR) and six partial responses (PR). The median time to progression for responders was 8 months (range: 2-36+); two patients with rituximab-refractory follicular lymphoma were in CR at 25 and 36+ months. The ORR was 55% (4 CRs, 2 PRs) in 11/14 patients with rituximab-refractory follicular lymphoma, and 100% in the three patients with rituximab-sensitive tumour. Most toxicities were low grade and transient, and myelotoxicity was uncommon.

KW - Denileukin difitox

KW - Follicular lymphoma

KW - Non-Hodgkin lymphoma

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=34447299909&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34447299909&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2141.2007.06684.x

DO - 10.1111/j.1365-2141.2007.06684.x

M3 - Article

C2 - 17608763

AN - SCOPUS:34447299909

SN - 0007-1048

VL - 138

SP - 502

EP - 505

JO - British Journal of Haematology

JF - British Journal of Haematology

IS - 4

ER -

Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B-cell non-Hodgkin lymphoma

Abstract

Keywords

ASJC Scopus subject areas

MD Anderson CCSG core facilities

Access to Document

Other files and links

Fingerprint

Cite this